Trial Profile
A 12-month Prospective Observational Study Assessing the Real-world Clinical Effectiveness, Safety and Health-economic Benefits of Toujeo Initiation After Oral Antidiabetic Drug Failure in Insulin-naïve Patients With Type 2 Diabetes Mellitus
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 27 Dec 2022
Price :
$35
*
At a glance
- Drugs Insulin glargine (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms ATOS
- Sponsors Sanofi
- 27 Dec 2022 Results of sub-group analysis assessing real-world effectiveness and safety of insulin glargine 300 U/ml (Gla-300) in achieving glycaemic goals in insulin-naive people with type 2 diabetes (T2D) in Mexico, Colombia and Peru, published in the Diabetes, Obesity and Metabolism.
- 23 Sep 2022 Results (n=3651) of post hoc analysis assessing the baseline factors and outcomes associated with different magnitudes of Gla-300titration in people initiating basal insulin presented at the 58th Annual Meeting of the European Association for the Study of Diabetes.
- 07 Jun 2022 Results assessing changes in treatment satisfaction and health status among participants, presented at the 82nd Annual Scientific Sessions of the American Diabetes Association.